Statin use and risk of hepatocellular carcinoma

European Journal of Epidemiology - Tập 28 Số 6 - Trang 485-492 - 2013
SW Lai1, Kuan-Fu Liao2, Hsueh‐Chou Lai3, Chih-Hsin Muo4, Fung-Chang Sung4, Pei‐Chun Chen5
1School of Medicine, China Medical University, Taichung, Taiwan
2Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
3School of Chinese Medicine, China Medical University, Taichung, Taiwan
4Department of Public Health, China Medical University, Taichung, Taiwan
5Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, No. 17 Xu-Zhou Road, Taipei, 10020, Taiwan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120:833–43.

Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008;44:2122–32.

Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121:302–9.

Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100:134–9.

Department of Health. Taiwan: Main causes of death in 2010. http://www.doh.gov.tw . [cited in 2012 January].

El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601–8.

Chiu HF, Ho SC, Chen CC, Yang CY. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol. 2011;106:894–8.

Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30:623–30.

Cabibbo G, Craxi A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2010;14:352–5.

Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res. 2007;37(Suppl 2):S101–5.

Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore). 2010;89:295–9.

Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol. 2011;106:1697–704.

Lai SW, Su LT, Lin CH, Tsai CH, Sung FC, Hsieh DP. Polypharmacy increases the risk of Parkinson’s disease in older people in Taiwan: a population-based study. Psychogeriatrics. 2011;11:150–6.

Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107:46–52.

Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10–9.

Friis S, Olsen JH. Statin use and cancer risk: an epidemiologic review. Cancer Invest. 2006;24:413–24.

Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010;9:603–21.

Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26–35.

Thông tin
Thông tin xuất bản

European Journal of Epidemiology

Tập 28 Số 6

485-492

Thông tin tác giả